Translational Informatics Division, Department of Internal Medicine, University of New Mexico School of Medicine, MSC10 5550, 1 University of New Mexico, Albuquerque, New Mexico 87131-0001, USA.
AAPS J. 2012 Dec;14(4):759-63. doi: 10.1208/s12248-012-9390-1. Epub 2012 Jul 24.
Repurposing drugs requires finding novel therapeutic indications compared to the ones for which they were already approved. This is an increasingly utilized strategy for finding novel medicines, one that capitalizes on previous investments while derisking clinical activities. This approach is of interest primarily because we continue to face significant gaps in the drug-target interactions matrix and to accumulate safety and efficacy data during clinical studies. Collecting and making publicly available as much data as possible on the target profile of drugs offer opportunities for drug repurposing, but may limit the commercial applications by patent applications. Certain clinical applications may be more feasible for repurposing than others because of marked differences in side effect tolerance. Other factors that ought to be considered when assessing drug repurposing opportunities include relevance to the disease in question and the intellectual property landscape. These activities go far beyond the identification of new targets for old drugs.
药物再利用需要找到与已批准用途不同的新的治疗适应症。这是一种越来越被用于寻找新药的策略，利用了之前的投资，同时降低了临床活动的风险。这种方法之所以受到关注，主要是因为我们在药物靶点相互作用矩阵方面仍然存在重大差距，并在临床研究中积累安全性和疗效数据。收集和公开尽可能多的关于药物靶点特征的数据为药物再利用提供了机会，但可能会通过专利申请限制商业应用。某些临床应用可能比其他应用更适合再利用，因为在副作用耐受性方面存在显著差异。在评估药物再利用机会时，还应考虑其他因素，包括与所关注疾病的相关性和知识产权状况。这些活动远远超出了为旧药物寻找新靶点的范围。
